New 2016 Data and Statistics for Global Pharmaceutical Products and

Editorial pubs.acs.org/chemneuro

New 2016 Data and Statistics for Global Pharmaceutical Products and Projections through 2017

T

he year 2016 was a healthy year for the global pharmaceutical industry once again, with 2016 sales estimates of ∼$967 billion ($446 billion, or 46%, in the United States alone).1 The drugs that made the top 10 in 2016 in terms of sales are conserved relative to 2015, with only slight changes in rank order (Table 1).2 AbbVie’s Humira (adalimumab, $16

Another interesting disparity resides in the spending in different therapy areas between developed markets (top 20 classes account for 71% of spending) and pharmerging markets (top 20 classes account for 45% of spending).5 In developed markets, oncology dominates with projected 2017 sales in the $74−84 billion range, while in pharmerging markets pain dominates (projected 2017 sales in the $22−25 billion range). In both markets, CNS drugs are well represented. In developed markets, pain accounts for $31−36 billion, other CNS drugs account for $26−31 billion, antiepileptics account for $15−18 billion, and antipsychotics, despite numerous patent expirations in the past 2 years, account for $13−16 billion.5 In pharmerging markets, pain accounts for $22−25 billion, other CNS drugs account for $20−23 billion, antiepileptics account for $3−5 billion, and antipsychotics account for $2−3billion.5 In total, total global spending on pharmaceuticals is expected to hit ∼$1.2 trillion in 2017, an increase of ∼$235 billion over 2012 sales.5 Where are the major payers of the ∼$1.2 trillion? The United States, The European Union (the EU5), Japan, and China will account for ∼70% (or $840 billion) of the total.4 Importantly, China is emerging as a true growth market (with 14−17% growth projected over the next 5 years), so be sure to nationalize your patents in China! Finally, generic medicines will continue to take an ever increasing share of the market, with 2017 projections of ∼21% of the total market in developed markets and ∼67% in pharmerging markets.5 The pharmaceutical market is strong, and poised to enter previously unforetold levels of sales and new markets in 2017 and beyond. Unlike previous years, biologics dominate the top 10 in terms of global sales. So many CNS disorders still represent unmet medical needs, and the market is prime for fundamentally new treatmentspatients are waitinglet us all not fail to deliver.

Table 1. Top 10 Global Prescription Drugs in 2016 in Terms of Sales2 rank

product

sales (US $BN)

1 2 3 4 5 6 7 8 9 10

Humira Harvoni Enbrel Rituxan Remicade Revimid Avastin Herceptin Lantus Prevnar

16.078 9.081 8.874 8.583 7.829 6.974 6.752 6.751 6.054 5.718

billion) displaced Gilead’s HCV cure combo Harvoni (ledipasvir/sofosbuvir, $9.1 billion) for the top spot, demonstrating an impressive 14.7% growth over 2015 ($14 billion). In contrast, Harvoni fell 34.5% versus 2015 sales numbers ($13.8 billion). As opposed to a global market dominated by small molecule therapeutics in the top 10 in years past, 2016 witnessed 9 out of the top 10 pharmaceutical products being biologics!3 In addition, EP Vantage Preview4 ranked the top 10 global pharmaceutical companies, and, as in 2015, Pfizer ranked number 1 in terms of 2016 sales: (1) Pfizer ($48 billion), (2) Novartis ($44.5 billion), (3) Roche ($39.8 billion), (4) Sanofi ($39.7 billion), (5) Merck ($37.9 billion), (6) GlaxoSMithKline ($33.5 billion), (7) Johnson & Johnson ($33.2 billion), (8) Gilead ($30.1 billion), (9) Abbvie ($26 billion and more than 50% derived from Humira sales), and (10) AstraZeneca ($22.7 billion). Multiple new drug launches in 2016 with blockbuster potential coupled with numerous patent expirations for leading biologics will shake up the top 10 in the coming years. Sadly, this is the first year that a CNS therapeutic has not been in the top 10. QuintilesIMS (formerly IMS Health)5 just released exciting new data on global spending trends on medicines through 2017, and I’ll relay some of these data here. As evidenced by Table 1, biologics, biosimilars, and nonoriginal biologics (NOB) products are increasing their share of the global pharmaceutical market, and dominating sales. For example, in 2002, biologics accounted for 11% ($46 billion) of global sales, but projections for 2017 show that biologics will expand to ∼20% ($212 billion) of global sales. In pharmerging markets (a new term to describe emerging pharmaceutical markets), with struggles to pay for branded biologics, NOBs are increasing.5 © 2017 American Chemical Society

■

Craig W. Lindsley, Editor-in-Chief AUTHOR INFORMATION

ORCID

Craig W. Lindsley: 0000-0003-0168-1445 Notes

Views expressed in this editorial are those of the author and not necessarily the views of the ACS.

■

REFERENCES

(1) https://www.statista.com/ statistics/272181/worldpharmaceutical-sales-by-region/. (2) Philippidis, A. http://www.genengnews.com/the-lists/the-top15-best-selling-drugs-of-2016/77900868. (3) Lindsley, C. W. (2016) (2016) 2015: A new impact factor for ACS Chemical Neuroscience and new topline data for global pharmaceutical products. ACS Chem. Neurosci. 7, 842−843. (4) http://info.evaluategroup.com/rs/607-YGS-364/images/ EPV2017Prev.pdf. Published: August 16, 2017 1635

DOI: 10.1021/acschemneuro.7b00253 ACS Chem. Neurosci. 2017, 8, 1635−1636

ACS Chemical Neuroscience

Editorial

(5) http://www.imshealth.com/en/about-us/news/top-line-marketdata.

1636

DOI: 10.1021/acschemneuro.7b00253 ACS Chem. Neurosci. 2017, 8, 1635−1636